Claims for Patent: 7,208,313

Summary for Patent: 7,208,313

Title:	Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
Abstract:	A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype.
Inventor(s):	McCart; J. Andrea (Toronto, CA), Bartlett; David L. (Pittsburgh, PA), Moss; Bernard (Bethesda, MD)
Assignee:	United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC) N/A (N/A)
Application Number:	09/991,721
Patent Claims:	1. An isolated recombinant WR strain vaccinia virus, said vaccinia virus comprising a mutation in a thymidine kinase (TK) gene of the genome of said vaccinia virus to produce a negative TK phenotype and comprising a mutation in at least one vaccinia virus growth factor (VVGF) gene of the genome of said vaccinia virus to produce a negative VVGF phenotype. 2. The composition of claim 1, wherein said vaccinia virus further comprises an exogenous nucleotide sequence. 3. The composition of claim 1, wherein said negative thymidine kinase phenotype results from a vaccinia virus thymidine kinase gene containing a deletion of nucleic acid sequence. 4. The composition of claim 1, wherein said negative thymidine kinase phenotype results from a vaccinia virus genome from which a thymidine kinase gene is deleted. 5. The composition of claim 1, wherein said negative thymidine kinase phenotype results from a vaccinia virus thymidine kinase gene containing an insertion of nucleic acid sequence. 6. The composition of claim 1, wherein said negative thymidine kinase phenotype results from a vaccinia virus thymidine kinase gene containing a substitution of nucleic acid sequence. 7. The composition of claim 1, wherein said negative vaccinia virus growth factor phenotype results from at least one vaccinia virus growth factor gene containing a deletion of nucleic acid sequence. 8. The composition of claim 7, wherein said deletion comprises a deletion of the EGF-receptor binding site encoding sequence of said vaccinia virus growth factor gene. 9. The composition of claim 1, wherein said negative vaccinia virus growth factor phenotype results from a vaccinia virus genome from which at least one vaccinia virus growth factor gene is deleted. 10. The composition of claim 1, wherein said negative vaccinia virus growth factor phenotype results from at least one vaccinia virus growth factor gene containing an insertion of nucleic acid sequence. 11. The composition of claim 1, wherein said negative vaccinia virus growth factor phenotype results from at least one vaccinia virus growth factor gene containing a substitution of nucleic acid sequence. 12. The composition of claim 2, wherein said exogenous nucleotide sequence is selected from the group consisting of tumor suppressor genes, cytotoxic genes, cytostatic genes, cytokine encoding genes, suicide genes, and antigen encoding genes. 13. The composition of claim 12, wherein said tumor suppressor gene is selected from the group consisting of WT1, p53, p16, Rb, and BRCA1. 14. The composition of claim 1, wherein said vaccinia virus is produced by a virus particle containing a virus genome, wherein expression of said genome produces a vaccinia virus with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype. 15. The composition of claim 1, wherein said vaccinia virus is constructed such that the gene for E. coli lacZ is inserted into the thymidine kinase (TK) or virus growth factor (VGF) gene. 16. The composition of claim 1, wherein said vaccinia virus is constructed such that the gene for enhanced green fluorescent protein (EGFP) is inserted into the thymidine kinase (TK) or virus growth factor (VGF) gene. 17. A product made by the method of: providing a WR strain vaccinia virus genome and constructing a recombinant WR strain vaccinia virus by; mutating at least one vaccinia virus growth factor gene of said vaccinia virus genome to produce a negative vaccinia virus growth factor phenotype; and mutating a thymidine kinase gene of said vaccinia virus genome to produce a negative thymidine kinase phenotype, whereby a recombinant WR strain vaccinia virus is constructed. 18. The composition of claim 2, wherein said exogenous nucleotide sequence is selected from the group consisting of cystic fibrosis transmembrane regulator (CFTR), Factor VIII, low density lipoprotein receptor, beta-galactosidase, alpha-galactosidase, beta-glucocerebrosidase, insulin, parathyroid hormone, and alpha-1-antitrypsin. 19. The composition of claim 2, wherein said exogenous nucleotide sequence is introduced to inactivate said TK gene. 20. The composition of claim 2, wherein said exogenous nucleotide sequence is introduced to inactivate said at least one VVGF gene. 21. The composition of claim 12, wherein said exogenous nucleotide sequence is a cytokine encoding gene. 22. The composition of claim 12, wherein said exogenous nucleotide sequence is a suicide gene. 23. The composition of claim 2, wherein said exogenous nucleotide sequence facilitates tumor imaging.

Details for Patent 7,208,313

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2019-05-28